Analysis of the Effectiveness of Various Types of Conservative Therapy for Chronic Bacterial Prostatitis


Ihor Gorpynchenko
Yurii Gurzhenko
Volodymyr Spyrydonenko


The management of patients with chronic bacterial prostatitis (CBP) is associated with a number of challenges. In particular, even in case of pathogen identification, targeted antimicrobial therapy does not reliably control the activity of the inflammatory process and pain syndrome. In addition to the pain syndrome, the clinical picture is aggravated by disorders of urination, sexual function and psycho-emotional sphere, which requires the inclusion of appropriate means of correction in the treatment program. In addition, as result of the chronic course of the disease, repeated and long courses of treatment should be carried out, putting forward additional requirements for the safety of the drugs used. Thus, the development of effective and safe protocols for the management of patients with CBP is an actual scientific task. Given the wide range of biological effects, plant and animal extracts have the potential to enhance the effectiveness of standard CBP treatment.

The objective: to compare the efficacy and safety of adding to the standard therapy (ST) CBP, regulated by the protocol of medical care of the Ministry of Health of Ukraine, biologically active plant substances (dwarf palm, stinging nettle, ginkgo biloba, Japanese bitterness, lovage, calendula officinalis) and animal (peptides isolated from the prostate of sexually mature gobies) origin in the form of capsules and suppositories.

Materials and methods. The study included 105 patients with CBP, aged from 26 to 39 years and duration of the disease from 6 months to 5 years. Depending on the treatment program, patients were randomized into three groups of equal size (n=35): group I – ST + 1 capsule and 1 rectal suppository per day with plant extracts (PE), group II – ST + 1 rectal suppository with PE per day, ІІІ group – ST + 1 rectal suppository with animal extract (AE). Composition of 1 capsule with PE: dwarf palm berry extract – 160 mg; stinging nettle extract – 100 mg; ginkgo biloba extract – 20 mg; Japanese knotweed extract – 20 mg; selenium methionine – 15 mg. Composition of 1 suppository with PE: extract of dwarf palm berries – 150 mg, extract of lovage roots – 50 mg, extract of calendula flowers – 50 mg. Composition of 1 suppository with AE: prostate extract of sexually mature bulls – 30 mg. The therapy lasted 30 days. At the end of therapy, the groups were compared with each other in terms of changes in pain syndrome (NIH CPSI), results of digital rectal examination, intensiveness of lower urinary tract symptoms (IPSS/QoL), sexual function (IIEF), activity of the inflammatory reaction of metabolism in the prostate (leukocyte count, lecithin grains in the field of view during light microscopy of prostatic secretion), the size of the prostate, the frequency of detection of sonographic artifacts (ultrasound examination), the maximum flow rate – Qmax, urination time – Tu (uroflowmetry), the frequency and nature of undesirable phenomena. To assess the significance of differences, the Student and Fisher tests were used. Significance level – 0.05.

Results. Initially, the following disorders were recorded in groups I, II and III: pain syndrome – in 45.7%, 37.1% and 40% of patients, respectively, dysuria – in 62.9%, 51.4% and 54.3%, premature ejaculation (PEj) – in 31.9%, 34.3%, 40%, erectile dysfunction (ED) – in 20%, 14.3%, 20%, calcifications in the prostate – in 45.7%, 40%, 34.3%, diffuse changes in the pancreas. The most common pathogen in all groups was Escherichia coli: it was identified in 42.9%, 54.3% and 60% of patients, respectively. The second and third places in the frequency of detection were taken by Streptococcus faecalis (38.1%) and Staphylococcus aureus (16.2%). At the end of therapy, a decrease in the intensity of pain sensations was recorded in all groups, but the most pronounced – in group I. Thus, in group I, the rate of decrease in the indicator was 15.8 times, in contrast to 4.3 times in group II, and 2.9 times in group III (p<0.001). Pain on palpation of the pancreas was arrested in 100% of patients in group I, in 91.4% in group II, in 88.6% in group III (p<0.001). The decrease in the intensity of dysuria was also more significant in group I. The addition of a combination of PE in the form of capsules and suppositories to ST was associated with a more pronounced decrease in the proportion of patients with PEj and ED. In group I, their share decreased by 3.7 and 3.5 times, respectively, while in group II – by 2 and 2.5 times, and in group III – by 2 and 2.3 times (p<0.001). All three modes of therapy effectively reduced the activity of the inflammatory reaction (a decrease in the number of leukocytes in the pancreas secretion in the field of view), but did not differ in the severity of this effect (p>0.05). Only in group I statistically significant changes in the frequency of daytime and nighttime urination were recorded, which decreased by 21% and 50%, respectively. Although IPSS and QoL improved in all groups, the groups, where PE were used, did not differ in the magnitude of changes in these parameters (p>0.05). The frequency of detecting diffuse and focal changes in the echostructure of the prostate also decreased in all three groups. All three treatment regimens significantly increased Qmax (on average by 1.7 times) and reduced Tu (on average by 1.66 times), but these effects did not differ statistically significantly. Also, there were no significant intergroup differences in the change in the integral indicator of the NIH CPSI scale and the effectiveness of pathogen eradication. In particular, in group I it decreased from 39.3±2.2 to 18.3±1.8 points (p<0.01); in group II – from 37.4±2.7 to 21.3±0.19 points (p<0.01); in group III – from 37.9±2.4 to 22.3±1.9 points (p<0.01). Eradication of the pathogen was achieved in 97.1%, 91.4% and 85.7%, respectively. All three therapeutic regimens were characterized by a satisfactory safety profile: adverse events in the form of a transient skin rash occurred in 1 (2.9%) patient from group I, in 2 (5.7%) patients from group II, and in 2 (5, 7%) of patients from group III. When comparing the groups in accordance with the integral assessment of treatment results, it was found that the proportion of patients assessing the effect as “high” was significantly higher in group I – 57.1% in contrast to 48.6% and 37.1% in II and III groups, respectively.

Conclusion. The multisyndromic nature of CBP makes it possible to include in the therapy program extracts of plant and animal origin, which have a wide range of biological effects. Adding of the PE in the form of capsules and rectal suppositories to standard treatment of CBP is scientifically approved, since it is statistically significantly more effective. than PE in the form of capsules and AE in the form of suppositories in correction of pain syndrome, sexual disorders, dysuria, day and night pollakiuria, and is characterized by a higher integral assessment of the effect. The effect of ST with the inclusion of PE in the form of capsules and rectal suppositories on the activity of inflammation, urination parameters, and pathogen eradication can be compared with that of ST + PE in the form of capsules and ST + AE in the form of suppositories. The addition of the plant and animal extracts to ST is safe. Long-term studies are required to evaluate the possibility of ST + PE in the form of capsules and rectal suppositories to influence the size of the prostate.


How to Cite
Gorpynchenko, I., Gurzhenko, Y., & Spyrydonenko, V. (2021). Analysis of the Effectiveness of Various Types of Conservative Therapy for Chronic Bacterial Prostatitis. Health of Man, (3), 35–48.
For practicing physicians
Author Biographies

Ihor Gorpynchenko, Ukrainian Institute of Sexology and Andrology

Ihor I. Gorpynchenko,


Yurii Gurzhenko, Ukrainian Institute of Sexology and Andrology

Yurii M. Gurzhenko

Volodymyr Spyrydonenko, Ukrainian Institute of Sexology and Andrology

Volodymyr V. Spyrydonenko


Dennis L, Lynch CF, Tornes JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60:78-83.

Horpynchenko Y.Y., Hurzhenko Yu.N., Spyrydonenko V.V. Teoretychni peredumovy ta praktychni mozhlyvosti efektyvnoho vykorystannia rektalnykh form samprostu pry khronichnomu prostatyti. Medyts. aspekty zdorovia muzhchiny. 2015;19:30-42.

Elkahwaji J.E., Zhong W., Bushman W. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis. Prostate. 2007;67:14-21.

Gorpinchenko I.I., Gurzhenko IU.N. Ispol’zovanie suppozitoriev Vitaprost forte i Vitaprost v kompleksnom lechenii bol’nykh khronicheskim nespecificheskim prostatitom. Health of man. 2011;4:86-8.

Chua T., Eise N.T, Simpson J.S., Ventura S. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility. J Ethnopharmacol. 2014. Mar 14;152(2):283-91.

Forray C., Bard J.A., Wetzel J.M. et al. The α1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human α1с subtype. Mol. Pharmacol. 1994;45(4):703-8.

Goldstraw M.A., Fitzpatrick J.M., Kirby R.S. What is the role of inflammation in the pathogenesis of prostate cancer. BJU Int. 2007;15:1-2.

Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-41.

Di Silverio F, Gentile V., De Matteis A., et al. Distribution of inflammation, premalignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. Eur Urol. 2003;43:164-75.

Bostanci Y.; Kazzazi A.; Momtahen S., Laze J., Djavan В. Correlation between benign prostatic hyperplasia and inflammation. Benign Prostatic Hyperplasia. 2013;23(1):5-10.

Gorpinchenko I.I., Romaniuk M.G., Aksenov P.V., Kornienko A.M. Svechi Pravenor – novoe slovo v fitoprofilaktike zabolevanij predstatel’noj zhelezy. Health of man. 2015;3(54):65-70.

Plosker GL, Brogden RN. Serenoa repens (Per-mixon). A review of its pharmacology and thera-peutic efficacy in benign prostatic hyperplasia. Drugs Aging. 1996;9:379-95.

Paubert-Braquet M et al. Effect of the lipido-sterolic extract of Serenoa. Prostaglandins Leukot Essent Fatty Acids. 1997;57:299-304.

Wu YN, Liao CH, Chen KC, Liu SP, Chiang HS. Effect of Ginkgo biloba Extract (EGb-761) on Recovery of Erectile Dysfunction in Bilateral Cavernous Nerve Injury Rat Model. Urology. 2015. May;85(5):1214-15.

Peng W, Qin R, Li X, Zhou H. Botany, phytochemistry, pharmacology, and potential application of Polygonum cuspidatum Zucc.: a review. J Ethnopharmacol. 2013. Jul 30;148(3):729-45.

Yun-Ting Z, Xiao H, Yun-Zhong C, Jun-de LI, Kun YU. Chemical constituents and their biosynthesis mechanisms of Polygonum cuspidatum. Article in Chinese Zhongguo Zhong Yao Za Zhi. 2020. Sep;45(18):4364-72.

Zhang X, Liu F, Feng ZM, Jiang JS, Yang YN, Zhang PC. Bioactive amides from Polygonum cuspidatum. J Asian Nat Prod Res. 2021. Mar;23(3):228-34.

Jinfeng Fu, Songyan Wu, Min Wang, Yuan Tian, Zunjian Zhang, Rui Song (2018) Intestinal metabolism of Polygonum cuspidatum in vitro and in vivo. Biomed Chromatogr. Jun;32(6):e4190.

Zhao XJ, Chen L, Zhao Y et al. Polygonum cuspidatum extract attenuates fructose-induced liver lipid accumulation through inhibiting Keap1 and activating Nrf2 antioxidant pathway, Phytomedicine. 2019. Oct; 63:152986.

Boyu Pan, Xiaona Shi, Tingting Ding, Liren Liu. Unraveling the action mechanism of polygonum cuspidatum by a network pharmacology approach. Am J Transl Res. 2019. Nov 15;11(11):6790-811.

Wu X, Li Q, Feng Y, Ji Q. Antitumor Research of the Active Ingredients from Traditional Chinese Medical Plant Polygonum Cuspidatum Xinnan Evid Based Complement Alternat Med. 2018. Nov 21;2018:2313021.

Spallholz JE. Selenomethionine and Methioninase: Selenium Free Radical Anticancer Activity.Methods Mol Biol. 2019;1866:199-210.

Santolo GM, Yamamoto JT, Neiberg PS, Wilson BW. Selenium accumulation in coturnix quail fed seleno-L-methionine. Environ Toxicol Chem. 2010. Oct;29(10):2220-4.

Moreda-Piñeiro J, Moreda-Piñeiro A, Romarís-Hortas V, Domínguez-González R, Alonso-Rodríguez E, López-Mahía P, Muniategui-Lorenzo S, Prada-Rodríguez D, Bermejo-Barrera P. In vitro bioavailability of total selenium and selenium species from seafood. Food Chem. 2013 Aug 5;139(1-4):872-7.

Zhao W, Zhai F, Han J. Effects of Selenium on Differentiation and Antioxidant Activity of Sclerotium of Penicillium thomii Q1 Strain. Biomed Res Int. 2020 Apr 26:2368245.

Arrigo F, Cicero G, Olta Allkanjari, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Arch Ital Urol Androl. 2019 Oct 2;91(3).

Dhouibi R, Affes H, Ben Salem M, Hammami S et al. Screening of pharmacological uses of Urtica dioica and others benefits. Prog Biophys Mol Biol. 2020 Jan;150:67-77.

Safarinejad M. R. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. J Herb Pharmacother. 2005;5(4):1-11.

Pigat N, Reyes-Gomez E, Boutillon F et al. Combined Sabal and Urtica Extracts (WSR1541) Exert Anti-proliferative and Anti-inflammatory Effects in a Mouse Model of Benign Prostate Hyperplasia. Front Pharmacol. 2019 Mar 29;10:311.

Ooi Soo Liang, Pak Sok Cheon. Serenoa repens for Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine J Altern Complement Med. 2017 Aug;23(8):599-606.

Saponaro M, Giacomini I, Morandin G. et al. Serenoa repens and Urtica dioica Fixed Combination: In-Vitro Validation of a Therapy for Benign Prostatic Hyperplasia (BPH) Int J Mol Sci. 2020 Dec 2;21(23):9178.

Miran M, Mehdi Feizabadi M, Kazemian H, et al. The activity of Levisticum officinale W.D.J. Koch essential oil against multidrug-resistant Mycobacterium tuberculosis. Iran J Microbiol. 2018 Dec;10(6):394-9.

Schinkovitz А, Stavri M, Gibbons S, Bucar F. Antimycobacterial polyacetylenes from Levisticum officinale. Phytother Res May. 2008;22(5):681-4.

Mascoloti Spréa R, Fernandes Â, Calhelha RC. et al. Chemical and bioactive characterization of the aromatic plant Levisticum officinale W.D.J. Koch: a comprehensive study. Food Funct. 2020 Feb 26;11(2):1292-1303.

Miran M, Esfahani HM, Jung JH et al. Characterization and Antibacterial Activity of Phthalides from the Roots of the Medicinal Herb Levisticum officinale W.D.J. Koch. Iran J Pharm Res. Spring. 2020;19(2):182-6.

Lovecka P, Lipov J, Thumova K, Macurkova A. Characterization of Biologically Active Substances from Calendula officinalis. Curr Pharm Biotechnol. 2017;18(14):1167-74.

Final report on the safety assessment of Calendula officinalis extract and Calendula officinalis. Int J Toxicol. 2001. 20 Suppl 2:13-20.

Calendula. Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006.

Givol O, Kornhaber R, Visentin D, Cleary M, Haik J, Harats M. A systematic review of Calendula officinalis extract for wound healing. Wound Repair Regen. 2019 Sep;27(5):548-61.

Foroutankhah M, Toghyani M, Landy N. Evaluation of Calendula officinalis L. (marigold) flower as a natural growth promoter in comparison with an antibiotic growth promoter on growth performance, carcass traits and humoral immune responses of broilers. Anim Nutr. 2019 Sep;5(3):314-8.

Kaur J, Sidhu S, Chopra K, Khan MU. Calendula officinalis ameliorates l-arginine-induced acute necrotizing pancreatitis in rats. Pharm Biol. 2016 Dec;54(12):2951-9.

Irani J, Levillian P, Gouion J.M, Bon D. et al. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol. 1997;157:1301-3.

Kramer G, Mitteregger D, Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 2007;51:1202-16.

Lowe F, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia. Curr. Opin. Urol. 2002;12:15.

Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237-41.

Nelson WG., De Marzo AM, Isaacs WB. Prostate cancer. N. Engl. J. Med. 2003;349:366-81.

Palapattu GS, Sutcliffe S, Bastain PJ., Platz EA. Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis. 2004;26:1170-81.

Platz E.A, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171:536-40.

Sugar LM. Inflammation and prostate cancer. Can J Urol. 2006;13(1):46-7.

Tomas D, Krušlin B, Rogatsch H et al. Different types of atrophy in the prostate with and without adenocarcinoma. Eur. Urol. 2007;51:98-104.

Nickel JC. Prostatic inflammation in BPH: the third component? Can. J Urol. 1994;1:1-4.

Zheng S. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res. 2004;64:2918-22.

Zheng SA. Comprehensive association study for genes in inflammation pathway provides support from their roles in prostate cancer risk in the CAPS study. Prostate. 2006;66:1556-64.

Vela-Navarrete R., Escribano-Burgos M., Farré A.L et al. Serenoa repens treatment modifies bax/bcl-2 index expression and caspase-3 activity in prostatic tissue from patients with benign prostatic hyperplasia. J Urol. 2005;173(2):507-10.